1,2,4-TRIAZINE-3-AMINE DERIVATIVES Russian patent published in 2022 - IPC A61K31/53 A61K31/5377 A61P35/00 C07D253/07 C07D401/04 C07D401/14 C07D403/04 C07D405/04 C07D405/10 

FIELD: pharmaceutical chemistry.

SUBSTANCE: group of inventions relates to the field of pharmaceutical chemistry, and it is the use of a compound of the formula A1 (its pharmaceutically acceptable salt) or 6-(2-chloro-6-methylpyridine-4-yl)-5-(4-fluorophenyl)-1,2,4-triazine-3-amine (its pharmaceutically acceptable salt) in the manufacture of a drug for the treatment of cancer mediated by the activity of A1 receptor and/or A2a receptor. In the formula A1, A is Cy^AA or Het^AA; Cy^AA is a 6-element aromatic carbocyclic system, where Cy^AA group has a substituent R^4a at position 3 relatively to the point of attachment to a triazine ring, and, if necessary, has one or more additional substituent R^4a; Het^AA is a 6-element heterocyclic group, which can be aromatic, fully saturated or partially unsaturated, and which contains one or two heteroatoms selected from O and N, while Het^AA group has a substituent R^4b at position 3 relatively to the point of attachment to the triazine ring, and, if necessary, has one or more additional substituent R^4b; B is Cy^BB or Het^BB; Cy^BB is phenyl optionally having one or more substituent R^4c; Het^BB is a 6-element aromatic heterocyclic group that contains one or two N atoms; R^4a-R^4c are as specified in the claims. It is provided that compound A1 is not 5-(2-chlorophenyl)-6-(3,4-dimethoxyphenyl)-[1,2,4]triazine-3-ylamine or 5-(2-chlorophenyl)-6-(3,4,5-trimethoxyphenyl)-[1,2,4]triazine-3-ylamine.

EFFECT: use of 1,2,4-triazine-3-amine derivatives in the production of a drug for the treatment of cancer mediated by the activity of A1 receptor and/or A2a receptor.

18 cl, 1 tbl, 7 ex